Initial-Dose Tarlatamab-Associated Tumor Lysis Syndrome in Small Cell Lung Cancer

A single 1-milligram starter dose of the cancer immunotherapy tarlatamab was followed by a fatal case of tumour lysis syndrome in a woman with relapsed small-cell lung cancer, according to a case report published in Respirology Case Reports. The rare but catastrophic complication emerged just six days after treatment, despite the patient initially experiencing only a mild, treatable immune reaction. The report highlights a potentially underrecognized danger of therapies that can destroy tumour cells with extraordinary speed: the cancer may disintegrate faster than the body can safely process the chemical debris released into the bloodstream. The authors say patients with small-cell lung cancer, particularly those with extensive liver metastases and signs of high tumour burden, may require more intensive prevention and monitoring for tumour lysis syndrome than current early-treatment observation practices provide.

Tumour lysis syndrome occurs when large numbers of malignant cells break apart over a short period, releasing their intracellular contents into the circulation. The resulting surge in potassium can trigger fatal cardiac rhythm disturbances, while phosphate binds circulating calcium and may cause severe biochemical instability. At the same time, the breakdown of nucleic acids produces uric acid, which can crystallize in the kidneys and contribute to acute kidney injury. The syndrome is well recognized after highly effective chemotherapy for blood cancers such as leukemia and lymphoma, but it is considered unusual in solid tumours. When it does occur in solid cancers, it is generally associated with widespread disease, an exceptionally large tumour burden, elevated lactate dehydrogenase—a marker of rapid cell turnover—and impaired organ function before treatment begins. Once kidney failure develops, the body’s ability to clear potassium, phosphate and uric acid deteriorates further, creating a rapidly accelerating medical emergency.

The treatment involved in the case, tarlatamab, belongs to a class of medicines called bispecific T-cell engagers, or BiTEs. Rather than acting indirectly through the immune system, the drug is designed to physically bring immune cells into contact with cancer cells. One end of tarlatamab binds delta-like ligand 3, or DLL3, a protein commonly displayed on small-cell lung cancer cells. The other binds CD3, a molecular component of T cells. This molecular bridge redirects cytotoxic T cells toward DLL3-bearing tumour cells and activates them to release substances that punch holes in the cancer-cell membrane and initiate cell death. The same immune activation can produce cytokine release syndrome, an inflammatory reaction caused by a sudden flood of signalling proteins. More severe immune toxicities can include immune effector cell-associated neurotoxicity syndrome, which affects brain function. These complications are recognized adverse effects of powerful T-cell therapies, but the new report suggests that the speed of tumour destruction itself may pose an additional threat.

The patient was a 61-year-old woman and a current smoker with a 41-year history of smoking approximately 20 cigarettes a day. Her cancer was initially identified after an abnormality appeared on a routine chest radiograph. Computed tomography revealed bulky disease around the right lung hilum, mediastinum and supraclavicular lymph nodes, along with a right upper-lobe pulmonary nodule considered likely to be an additional tumour deposit. Bronchoscopic biopsy confirmed limited-stage small-cell lung cancer classified as stage IIIC. She received four cycles of cisplatin plus etoposide alongside accelerated, twice-daily thoracic radiotherapy delivering 45 gray in 30 fractions. Treatment was followed by durvalumab, an immune checkpoint inhibitor intended to maintain anti-tumour immune activity, but that therapy was stopped after two cycles because she developed radiation pneumonitis. The lung inflammation improved with prednisolone, although the steroid dose remained at 15 milligrams per day when her later deterioration began.

The disease subsequently returned with strikingly extensive metastases in the liver. Tumour markers rose sharply, including neuron-specific enolase to 1,250 nanograms per millilitre and pro-gastrin-releasing peptide to 181.8 picograms per millilitre. Liver-function testing on admission already indicated hepatic failure, suggesting that the metastatic burden was not merely extensive on scans but was compromising a major organ responsible for metabolism, detoxification and biochemical balance. Because the cancer was progressing rapidly, clinicians started tarlatamab as second-line treatment using a 1-milligram dose on Day 1. The dose was part of a step-up approach intended to reduce the likelihood and severity of immune toxicity. Yet the small initial amount did not prevent a dangerous biological response. On Day 2, the patient developed fever and fatigue consistent with cytokine release syndrome. Dexamethasone improved those symptoms, and she appeared stable on Days 4 and 5.

That apparent stabilization was followed by an abrupt collapse. On Day 6, the woman developed respiratory failure and impaired consciousness. Laboratory testing showed a dramatic biochemical transformation compared with the previous day. Lactate dehydrogenase had climbed to 14,058 units per litre, indicating extensive tissue or tumour-cell destruction. Potassium reached 8.4 milliequivalents per litre, a level capable of causing lethal cardiac arrhythmias. Phosphorus rose to 11.4 milligrams per decilitre, while uric acid reached 16.2 milligrams per decilitre. These abnormalities occurred alongside acute kidney injury. Together, the findings satisfied the laboratory criteria for tumour lysis syndrome established by the Cairo–Bishop classification, which evaluates changes in uric acid, potassium, phosphate and calcium around the time of cancer treatment. The accompanying organ damage meant the patient had progressed to clinical tumour lysis syndrome, not merely an abnormal laboratory pattern. Her respiratory failure worsened rapidly despite further dexamethasone given for suspected cytokine release syndrome, and she died later that day.

The timing and mechanism distinguish this case from many conventional treatment-related toxicities. Immune checkpoint inhibitors work by releasing inhibitory brakes on T cells, a process that may require days or weeks to generate a clinically obvious response. Tarlatamab, by contrast, directly positions T cells next to DLL3-positive cancer cells. Because small-cell lung cancer commonly expresses DLL3, the drug can potentially mobilize cytotoxic lymphocytes without relying as heavily on tumour antigen presentation or on a pre-existing anti-cancer immune response. The early cytokine release syndrome in this patient indicates that T-cell activation was already occurring soon after the first dose. That activation may have triggered a wave of tumour-cell lysis large enough to overwhelm the patient’s liver and kidneys. The report notes that only one case of tumour lysis syndrome was recorded as an adverse event in a clinical trial of tarlatamab, while two previously reported cases associated with the drug also ended fatally. One of those patients developed the syndrome on Day 3 after receiving a single 1-milligram dose, closely resembling the present case.

The apparent rarity of tumour lysis syndrome in clinical trials may not fully capture the danger faced by patients with the most aggressive disease. Trial participants are often carefully selected, closely monitored and treated under protocols that may exclude people with severe organ dysfunction or unusually extensive metastases. Small-cell lung cancer is especially susceptible to rapid treatment responses because it grows quickly and can carry a large, highly treatment-sensitive tumour burden. Liver metastases may amplify the risk by occupying substantial tissue volume, raising lactate dehydrogenase and impairing hepatic function before therapy begins. The authors point to a concerning pattern: previously described cases of tarlatamab-associated tumour lysis syndrome and a case involving nivolumab in small-cell lung cancer occurred in patients with extensive liver metastases. This does not prove that liver involvement causes the syndrome, but it identifies a clinical feature that may help doctors recognize patients at elevated risk before an immune engager is administered.

The case also exposes a monitoring problem. Standard observation for cytokine release syndrome may focus on the first 48 hours after treatment, yet immune-mediated tumour lysis may develop later and with little warning. In this patient, there was no laboratory evidence of tumour lysis on Day 5, but fulminant metabolic collapse occurred the following day. A normal result shortly before deterioration therefore may not guarantee safety when the underlying tumour burden is extreme. The report argues that high-risk patients may need monitoring for tumour lysis beyond the usual early window used for cytokine release syndrome. Preventive measures could include aggressive intravenous hydration and medication to lower uric acid, although the appropriate strategy must be tailored to hepatic, renal and cardiovascular status. The clinicians’ central warning is not that tarlatamab should be abandoned, but that its ability to produce rapid and targeted T-cell killing demands a broader risk assessment before the first dose. In selected patients, preventing the metabolic consequences of tumour destruction may be as important as controlling the immune reaction itself.

Small-cell lung cancer remains one of the most aggressive human malignancies, with relapse frequently occurring after an initial response to chemoradiotherapy. Treatments such as tarlatamab offer a new way to exploit the immune system against recurrent disease, particularly by targeting DLL3, but the biology that makes these therapies powerful can also make their complications sudden and severe. This fatal case demonstrates that even a step-up dose of only 1 milligram can be followed by tumour lysis syndrome when a patient has rapidly progressing cancer, extensive liver metastases, high lactate dehydrogenase and pre-existing hepatic dysfunction. The findings come from one patient and cannot establish the frequency of the complication or define a universal prevention protocol. They do, however, provide a clinically urgent signal. For people with heavily metastatic small-cell lung cancer, especially when the liver is extensively involved, the first dose of tarlatamab may require prolonged biochemical surveillance, preparation for rapid intervention and proactive consideration of tumour lysis prevention from the outset.